^
    4d
    First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study. (PubMed, Clin Cancer Res)
    SG plus pembrolizumab and carboplatin had activity in mNSCLC. When combined with pembrolizumab and carboplatin, SG was tolerated at a dose of 7.5 mg/kg.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • Trodelvy (sacituzumab govitecan-hziy)
    6d
    SHR-A1921-205: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=124 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    9d
    Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Jiataile (sacituzumab tirumotecan)
    9d
    The Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas. (PubMed, Int J Surg Pathol)
    No significant association was found between TROP2 expression and other histological parameters.ConclusionLoss of ≥50% nuclear 5-hmC is a sensitive and specific marker for distinguishing mesothelioma from RMH. High TROP2 expression in tumors with high mitotic figures and higher nuclear and tumor grade suggests these patients may benefit from sacituzumab govitecan therapy.
    Journal
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    9d
    Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. (PubMed, Ann Oncol)
    Dato-DXd demonstrated significantly improved PFS and OS versus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. Safety was consistent with the known profile for Dato-DXd.
    P3 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Datroway (datopotamab deruxtecan-dlnk)
    12d
    QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Qibeian (iparomlimab/tuvonralimab)
    12d
    TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. (PubMed, J Immunother Cancer)
    This study defines a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CLDN7 (Claudin 7) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Trodelvy (sacituzumab govitecan-hziy)
    12d
    Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale. (PubMed, Drugs)
    By contrast, sacituzumab govitecan is a TROP-2-targeted ADC conjugated through a hydrolysable CL2A linker to SN-38, the active metabolite of irinotecan. Clinically, trastuzumab deruxtecan has shown substantial efficacy in both HER2-positive and HER2-low breast cancer, whereas sacituzumab govitecan has demonstrated efficacy across triple-negative and hormone receptor-positive/HER2-negative breast cancers. Collectively, these agents highlight how variations in target antigen, linker chemistry, and payload potency impact ADC activity, therapeutic index, and potential strategies for sequential treatment in advanced breast cancer.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • irinotecan • Trodelvy (sacituzumab govitecan-hziy)
    12d
    Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer. (PubMed, Front Pharmacol)
    SHR-A1921 is a promising Trop-2-targeted ADC that leverages innovative technology to deliver potent antitumor activity against Trop-2-expressing prostate cancer cells, with an acceptable safety profile observed in preclinical studies. These results highlight the promising clinical potential of SHR-A1921 as a therapeutic option for prostate cancer patients with Trop-2-positive tumors.
    Preclinical • Journal
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    tizetatug rezetecan (SHR-A1921)
    12d
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 overexpression • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    14d
    MEDOPP824: Phase II study to improve sacituzumab govitecan tolerance with atropine in patients with advanced triple-negative and hormone receptor-positive/HER2-negative breast cancer (The SATROPIN Study). (2025-524109-33-00)
    P1/2, N=30, Not yet recruiting, Medica Scientia Innovation Research S.L.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim)